GSA CAPITAL PARTNERS LLP

Position in ENTA — Enanta Pharmaceuticals Inc

CIK 1362033 LONDON, X0

Position in ENTA

as of Jun 30, 2026 · filed Aug 6, 2026 Compact

Position Value

$473,645

+$259,909 QoQ

Shares Held

32,486

+81.9% QoQ

Ownership

0.112%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

#53

of 122 holders

Holding Since

Jun 2020

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. ENTA ranks #80 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IOVA	Iovance Biotherapeutics, Inc.	655,318	$2,726,122
2	IMVT	Immunovant, Inc.	65,267	$2,514,737
3	GOSS	Gossamer Bio, Inc.	187,337	$2,472,846
4	AXSM	Axsome Therapeutics, Inc.	9,419	$2,305,488
5	CABA	Cabaletta Bio, Inc.	668,563	$2,079,230
6	MLTX	MoonLake Immunotherapeutics	106,695	$2,077,351
7	ATYR	aTYR PHARMA INC	3,454,863	$2,062,553
8	CORT	Corcept Therapeutics Inc	23,257	$2,022,196

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$473,645	32,486	+81.9%	Shares	Sole	2026-08-06
2025-09-30	$213,736	17,856	-70.3%	Shares	Sole	2025-11-07
2025-03-31	$332,083	60,160	+95.8%	Shares	Sole	2025-05-08
2024-12-31	$176,674	30,726	+6.8%	Shares	Sole	2025-02-07
2023-12-31	$270,725	28,770	+24.8%	Shares	Sole	2024-02-16
2023-09-30	$257,557	23,058	-27.9%	Shares	Sole	2023-11-15
2023-06-30	$684,200	31,972	-16.9%	Shares	Sole	2023-08-14
2023-03-31	$1,556,656	38,493	+248.1%	Shares	Sole	2023-05-12
2022-12-31	$514,371	11,057	+76.0%	Shares	Sole	2023-02-13
2021-06-30	$276,426	6,281	-41.4%	Shares	Sole	2021-08-05
2020-09-30	$490,532	10,715	+159.3%	Shares	Sole	2020-11-06
2020-06-30	$207,467	4,132	—	Shares	Sole	2020-08-11
No filing history on record for this holder in this stock.